A Study of INCB050465 in Primary Sjögren's Syndrome

Completed · Phase 2

Conditions studied: Primary Sjögren's Syndrome

In brief

The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of Sjögren's syndrome (SS).

Key facts

Study ID

NCT03627065

Run by

Incyte Corporation

People needed

10

Starts

2019-02-28

Expected to finish

2020-01-02

Last updated by the study team

2021-08-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary SS diagnosed according to the revised American-European Consensus Group (AECG) criteria.
• Minimum score of 2 on the SGUS score for parotid and submandibular glands.
• EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score ≥ 5.
• Positive serum titers of anti-SS-A and/or anti-SS-B antibodies.
• Symptomatic oral dryness score of at least 5 on patient questionnaire.
• Willingness to avoid pregnancy or fathering children based on protocol-defined criteria.

You may not qualify if…

• Diagnosis of secondary SS according to the revised AECG criteria (eg, the presence of a previously diagnosed or a present diagnosis of rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, mixed connective tissue disease, polymyositis, dermatomyositis, immunoglobulin G4-related disorder, sarcoidosis, or any other defined autoimmune rheumatologic disorder).
• Concurrent conditions and history of other diseases per protocol-defined criteria.
• Positive test results for tuberculosis (TB) from the QuantiFERON-TB Gold test or T-spot.TB test.
• Positive serology test results for HIV antibody, hepatitis B surface antigen, hepatitis B surface antigen antibody, HBV core antibody, or HCV (HCV antibody with positive HCV-RNA).
• Severely impaired liver function (Child-Pugh Class C).
• Prior or ongoing therapy with protocol-defined drugs.
• Receipt of any live vaccine in the 30 days before screening.
• No major surgery within 30 days before screening. Inadequate recovery from toxicity and/or complications from a major surgery before starting therapy.
• Current alcohol or drug use that, in the opinion of the investigator, will interfere with the participant's ability to comply with the dose regimen and study evaluations.
• Laboratory values at screening outside the protocol-defined ranges.

Where it is running

• Advanced Pharma CR — Miami, Florida, United States
• North Georgia Rheumatology Group — Lawrenceville, Georgia, United States
• The Center for Rheumatology and Bone Research — Wheaton, Maryland, United States
• Ramesh C. Gupta, MD — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.